

# Summary of Product Characteristics

## 1 NAME OF THE MEDICINAL PRODUCT

Gastrolief 20 mg gastro-resistant tablets

## 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each gastro-resistant tablet contains 20 mg pantoprazole (as sodium sesquihydrate).

Excipients with known effect: 38.425 mg Maltitol and 0.345 mg Lecithin (derived from soya oil) (see section 4.4)

For the full list of excipients, see section 6.1.

## 3 PHARMACEUTICAL FORM

Gastro-resistant tablet

Yellow, oval tablet.

## 4 CLINICAL PARTICULARS

### 4.1 Therapeutic Indications

Gastrolief 20 mg gastro-resistant tablets is indicated for short-term treatment of reflux symptoms (e.g. heartburn, acid regurgitation) in adults.

### 4.2 Posology and method of administration

#### Posology

The recommended dose is 20 mg pantoprazole (one tablet) per day.

It might be necessary to take the tablets for 2-3 consecutive days to achieve improvement of symptoms. Once complete relief of symptoms has occurred, treatment should be discontinued. The treatment should not exceed 4 weeks without consulting a doctor.

If no symptom relief is obtained within 2 weeks of continuous treatment, the patient should be instructed to consult a doctor.

#### Special populations

No dose adjustment is necessary in elderly patients or in those with impaired renal or liver function.

#### Paediatric population

Pantoprazole is not recommended for use in children and adolescents below 18 years of age due to insufficient data on safety and efficacy.

#### Method of administration

Gastrolief 20 mg gastro-resistant tablets should not be chewed or crushed, and should be swallowed whole with liquid before a meal.

### 4.3 Contraindications

Hypersensitivity to the active substance, lecithin (derived from soya oil) or to any of the excipients listed in section 6.1.

Co-administration with atazanavir (see section 4.5).

#### 4.4 Special warnings and precautions for use

Patients should be instructed to consult a doctor if:

- They have unintentional weight loss, anaemia, gastrointestinal bleeding, dysphagia, persistent vomiting or vomiting with blood, since it may alleviate symptoms and delay diagnosis of a severe condition. In these cases, malignancy should be excluded.
- They have had previous gastric ulcer or gastrointestinal surgery.
- They are on continuous symptomatic treatment of indigestion or heartburn for 4 or more weeks.
- They have jaundice, hepatic impairment, or liver disease.
- They have any other serious disease affecting general well-being.
- They are aged over 55 years with new or recently changed symptoms.

Patients with long-term recurrent symptoms of indigestion or heartburn should see their doctor at regular intervals. Especially, patients over 55 years taking any non-prescription indigestion or heartburn remedy on a daily basis should inform their pharmacist or doctor.

Patients should not take another proton pump inhibitor or H<sub>2</sub> antagonist concomitantly.

Patients should consult their doctor before taking this medicinal product if they are due to have an endoscopy or urea breath test.

Patients should be advised that the tablets are not intended to provide immediate relief.

Patients may start to experience symptomatic relief after approximately one day of treatment with pantoprazole, but it might be necessary to take it for 7 days to achieve complete heartburn control. Patients should not take pantoprazole as a preventive medicinal product.

##### Gastrointestinal infections caused by bacteria

Decreased gastric acidity, due to any means - including proton pump inhibitors - increases gastric counts of bacteria normally present in the gastrointestinal tract. Treatment with acid-reducing medicinal products leads to a slightly increased risk of gastrointestinal infections such as *Salmonella*, *Campylobacter*, or *Clostridium difficile*.

##### Subacute cutaneous lupus erythematosus (SCLE)

Proton pump inhibitors are associated with very infrequent cases of SCLE. If lesions occur, especially in sun-exposed areas of the skin, and if accompanied by arthralgia, the patient should seek medical help promptly and the health care professional should consider stopping pantoprazole. SCLE after previous treatment with a proton pump inhibitor may increase the risk of SCLE with other proton pump inhibitors.

##### Interference with laboratory tests

Increased Chromogranin A (CgA) level may interfere with investigations for neuroendocrine tumours. To avoid this interference, lansoprazole treatment should be stopped for at least 5 days before CgA measurements (see section 5.1). If CgA and gastrin levels have not returned to reference range after initial measurement, measurements should be repeated 14 days after cessation of proton pump inhibitor treatment.

This medicinal product contains maltitol.

Patients with rare hereditary problems of fructose intolerance should not take this medicinal product.

#### 4.5 Interaction with other medicinal products and other forms of interactions

Pantoprazole may reduce the absorption of active substances whose bioavailability is dependent on the gastric pH, e.g. some azole antifungals as ketoconazole, itraconazole, posaconazole and other medicine as erlotinib.

It has been shown that co-administration of atazanavir 300 mg/ritonavir 100 mg with omeprazole (40 mg once daily) or atazanavir 400 mg with lansoprazole (60 mg single dose) to healthy volunteers resulted in a substantial reduction in the bioavailability of atazanavir. The absorption of atazanavir is pH-dependent. Therefore, pantoprazole must not be co-administered with atazanavir (see section 4.3).

Although no interaction during concomitant administration of phenprocoumon or warfarin has been observed in clinical pharmacokinetic studies, a few isolated cases of changes in International Normalised Ratio (INR) have been reported during concomitant treatment in the post-marketing period. Therefore, in patients treated with coumarin anticoagulants (e.g. phenprocoumon or warfarin), monitoring of prothrombin time/INR is recommended after initiation, termination or during irregular use of pantoprazole.

Concomitant use of high dose methotrexate (e.g. 300 mg) and proton-pump inhibitors has been reported to increase methotrexate levels in some patients. Therefore in settings where high-dose methotrexate is used, for example cancer and psoriasis, a temporary withdrawal of pantoprazole may need to be considered.

Pantoprazole is metabolised in the liver via the cytochrome P450 enzyme system. Interaction studies with carbamazepine, caffeine, diazepam, diclofenac, digoxin, ethanol, glibenclamide, metoprolol, naproxen, nifedipine, phenytoin, piroxicam, theophylline and an oral contraceptive containing levonorgestrel and ethinyl oestradiol did not reveal clinically significant interactions. However, an interaction of pantoprazole with other substances which are metabolised by the same enzyme system cannot be excluded.

There were no interactions with concomitantly administered antacids.

#### 4.6 Fertility, pregnancy and lactation

##### Pregnancy

There are no adequate data from the use of pantoprazole in pregnant women. Studies in animals have shown reproductive toxicity. Preclinical studies revealed no evidence of impaired fertility or teratogenic effects (see section 5.3). The potential risk for humans is unknown. Pantoprazole should not be used during pregnancy.

##### Breastfeeding

It is unknown whether pantoprazole is excreted in human breast milk. Animal studies have shown excretion of pantoprazole in breast milk. Pantoprazole should not be used during breastfeeding.

##### Fertility

There was no evidence of impaired fertility following the administration of pantoprazole in animal studies (see section 5.3).

#### 4.7 Effects on ability to drive and use machines

Pantoprazole has no or negligible influence on the ability to drive and use machines. However, adverse reactions such as dizziness and visual disturbances may occur (see section 4.8). If affected, patients should not drive or use machines.

#### 4.8 Undesirable effects

##### Summary of the safety profile

Approximately 5 % of patients can be expected to experience adverse reactions. The most commonly reported adverse reactions are diarrhoea and headache, both occurring in approximately 1 % of patients.

##### Tabulated list of adverse reactions

The following adverse reactions have been reported with pantoprazole.

Within the following table, adverse reactions are ranked under the following frequency classification:

Very common ( $\geq 1/10$ ); common ( $\geq 1/100$  to  $< 1/10$ ); uncommon ( $\geq 1/1,000$  to  $< 1/100$ ); rare ( $\geq 1/10,000$  to  $< 1/1,000$ ); very rare ( $< 1/10,000$ ), not known (cannot be estimated from the available data).

Within each frequency grouping adverse reactions are presented in order of decreasing seriousness.

*Table 1. Adverse reactions with pantoprazole in clinical trials and post-marketing experience*

<b>Frequency</b>	<b>Common</b>	<b>Uncommon</b>	<b>Rare</b>	<b>Very rare</b>	<b>Not known</b>
<b>System Organ Class</b>					
<b>Blood and lymphatic system disorders</b>			Agranulocytosis	Thrombocytopenia; Leukopenia; Pancytopenia	
<b>Immune system disorders</b>			Hypersensitivity (incl. anaphylactic reactions and anaphylactic shock)		
<b>Metabolism and nutrition disorders</b>			Hyperlipidaemias and lipid increases (triglycerides, cholesterol); Weight changes		Hyponatraemia; Hypomagnesaemia
<b>Psychiatric disorders</b>		Sleep disorders	Depression (and all aggravations)	Disorientation (and all aggravations)	Hallucination; Confusion (especially in pre-disposed patients, as well as the aggravation of these symptoms in case of pre-existence)
<b>Nervous system disorders</b>		Headache; Dizziness	Taste disorders		
<b>Eye disorders</b>			Disturbances in vision / blurred vision		
<b>Gastrointestinal disorders</b>	Fundic gland polyps (benign)	Diarrhoea; Nausea / vomiting; Abdominal distension and bloating; Constipation; Dry mouth; Abdominal pain and discomfort			Microscopic colitis
<b>Hepatobiliary disorders</b>		Liver enzymes increased (transaminases, $\gamma$ -GT)	Bilirubin increased		Hepatocellular injury; Jaundice; Hepatocellular failure
<b>Skin and subcutaneous tissue disorders</b>		Rash / exanthema / eruption; Pruritus	Urticaria; Angioedema		Stevens-Johnson syndrome; Lyell syndrome; Erythema multiforme; Photosensitivity; Subacute cutaneous lupus erythematosus (see section 4.4)
<b>Musculoskeletal and connective tissue disorders</b>			Arthralgia; Myalgia		
<b>Renal and urinary</b>					Interstitial nephritis

<b>disorders</b>					
<b>Reproductive system and breast disorders</b>			Gynaecomastia		
<b>General disorders and administration site conditions</b>		Asthenia, fatigue and malaise	Body temperature increased; Oedema peripheral		

#### Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6762517. Website: [www.hpra.ie](http://www.hpra.ie); E-mail: [medsafety@hpra.ie](mailto:medsafety@hpra.ie).

## 4.9 Overdose

Doses up to 240 mg administered intravenously over 2 minutes, were well tolerated. As pantoprazole is extensively protein bound, it is not readily dialysable.

In the case of overdose with clinical signs of intoxication, apart from symptomatic and supportive treatment, no specific therapeutic recommendations can be made.

## 5 PHARMACOLOGICAL PROPERTIES

### 5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Drugs for acid related disorders, Proton pump inhibitors, ATC code: A02BC02

#### Mechanism of action

Pantoprazole is a substituted benzimidazole which inhibits the secretion of hydrochloric acid in the stomach by specific blockade of the proton pumps of the parietal cells.

Pantoprazole is converted to its active form, a cyclic sulphenamide, in the acidic environment in the parietal cells where it inhibits the H<sup>+</sup>, K<sup>+</sup>-ATPase enzyme, i. e. the final stage in the production of hydrochloric acid in the stomach. The inhibition is dose-dependent and affects both basal and stimulated acid secretion. In most patients, freedom from heartburn and acid reflux symptoms is achieved in 1 week. Pantoprazole reduces acidity in the stomach and thereby increases gastrin in proportion to the reduction in acidity. The increase in gastrin is reversible. Since pantoprazole binds to the enzyme distal to the receptor level, it can inhibit hydrochloric acid secretion independently of stimulation by other substances (acetylcholine, histamine, gastrin). The effect is the same whether the active substance is given orally or intravenously.

The fasting gastrin values increase under pantoprazole. On short-term use, in most cases they do not exceed the upper limit of normal. During long-term treatment, gastrin levels double in most cases. An excessive increase, however, occurs only in isolated cases. As a result, a mild to moderate increase in the number of specific endocrine (ECL) cells in the stomach is observed in a minority of cases during long-term treatment (simple to adenomatoid hyperplasia). However, according to the studies conducted so far, the formation of carcinoid precursors (atypical hyperplasia) or gastric carcinoids as were found in animal experiments (see section 5.3) have not been observed in humans.

#### Clinical efficacy

In a retrospective analysis of 17 studies in 5,960 patients with gastro-oesophageal reflux disease (GORD) who were treated with 20 mg pantoprazole monotherapy, the symptoms associated with acid reflux e.g. heartburn and acid regurgitation were evaluated according to a standardised methodology. Studies selected had to have at least one acid reflux symptom recording point at 2 weeks. GORD diagnosis in these studies was based on endoscopic assessment, with the exception of one study in which the inclusion of the patients was based on symptomatology alone.

In these studies, the percentage of patients experiencing complete relief from heartburn after 7 days was between 54.0 % and 80.6 % in the pantoprazole group. After 14 and 28 days, complete heartburn relief was experienced in 62.9 % to 88.6 % and 68.1 % to 92.3 % of the patients, respectively.

For the complete relief from acid regurgitation, similar results were obtained as for heartburn. After 7 days the percentage of patients experiencing complete relief from acid regurgitation was between 61.5 % and 84.4 %, after 14 days between 67.7 % and 90.4 %, and after 28 days between 75.2 % and 94.5 %, respectively.

Pantoprazole was consistently shown to be superior to placebo and H2RA and non-inferior to other PPIs. Acid-reflux symptom relief rates were largely independent of the initial GORD stage.

During treatment with antisecretory medicinal products, serum gastrin increases in response to the decreased acid secretion. Also CgA increases due to decreased gastric acidity. The increased CgA level may interfere with investigations for neuroendocrine tumours. Available published evidence suggests that proton pump inhibitors should be discontinued between 5 days and 2 weeks prior to CgA measurements. This is to allow CgA levels that might be spuriously elevated following PPI treatment to return to reference range.

## 5.2 Pharmacokinetic properties

Pharmacokinetics do not vary after single or repeated administration. In the dose range of 10 to 80 mg, the plasma kinetics of pantoprazole are linear after both oral and intravenous administration.

### Absorption

Pantoprazole is completely and rapidly absorbed after oral administration. The absolute bioavailability from the tablet was found to be about 77 %. On average, at about 2.0 h - 2.5 h post administration ( $t_{max}$ ) of a single 20 mg oral dose, the maximum serum concentrations ( $C_{max}$ ) of about 1-1.5 µg/ml are achieved, and these values remain constant after multiple administration. Concomitant intake of food had no influence on bioavailability (AUC or  $C_{max}$ ), but increased the variability of the lag-time ( $t_{lag}$ ).

### Distribution

Volume of distribution is about 0.15 l/kg and serum protein binding is about 98 %.

### Biotransformation

Pantoprazole is almost exclusively metabolised in the liver.

### Elimination

Clearance is about 0.1 l/h/kg, and terminal half-life ( $t_{1/2}$ ) about 1 h. There were a few cases of subjects with delayed elimination. Due to the specific binding of pantoprazole to the proton pumps within the parietal cell, the elimination half-life does not correlate with the much longer duration of action (inhibition of acid secretion).

Renal elimination represents the major route of excretion (about 80 %) for the metabolites of pantoprazole; the rest is excreted with the faeces. The main metabolite in both serum and urine is desmethylpantoprazole, which is conjugated with sulphate. The half-life of the main metabolite (about 1.5 h) is not much longer than that of pantoprazole.

### Special populations

#### Renal impairment

No dose reduction is recommended when pantoprazole is administered to patients with impaired renal function (including patients on dialysis, which removes only negligible amounts of pantoprazole). As with healthy subjects, the half-life of pantoprazole is short. Although the main metabolite has a longer half-life (2-3 h), excretion is still rapid and thus accumulation does not occur.

#### Hepatic impairment

After administration of pantoprazole to patients with liver impairment (Child-Pugh classes A, B and C) the half-life values increased to between 3 and 7 h and the AUC values increased by a factor of 3-6, whereas the  $C_{max}$  only increased slightly by a factor of 1.3 compared with healthy subjects.

#### Elderly

The slight increase in AUC and  $C_{max}$  in elderly volunteers compared with younger subjects was not clinically relevant.

## 5.3 Preclinical safety data

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity and genotoxicity.

In the 2-year carcinogenicity studies in rats, neuroendocrine neoplasms were found. In addition, squamous cell papillomas were found in the forestomach of rats in one study. The mechanism leading to the formation of gastric carcinoids by substituted benzimidazoles has been carefully investigated and allows the conclusion that it is a secondary reaction to the massively elevated serum gastrin levels occurring in the rat during chronic high-dose treatment.

In the 2-year rodent studies an increased number of liver tumours was observed in rats (in one rat study only) and in female mice and was interpreted as being due to pantoprazole's high metabolic rate in the liver.

A slight increase of neoplastic changes of the thyroid was observed in the group of rats receiving the highest dose (200 mg/kg) in one 2-year study. The occurrence of these neoplasms is associated with the pantoprazole-induced changes in the breakdown of thyroxine in the rat liver. As the therapeutic dose in man is low, no side effects on the thyroid glands are expected.

In animal studies (rats) 5 mg/kg was the observed NOAEL (No Observed Adverse Effect Level) for embryotoxicity. Investigations revealed no evidence of impaired fertility or teratogenic effects.

Penetration of the placenta was investigated in the rat and was found to increase with advanced gestation. As a result, concentration of pantoprazole in the foetus is increased shortly before birth.

## 6 PHARMACEUTICAL PARTICULARS

### 6.1 List of excipients

#### *Tablet core*

Maltitol (E965)  
Crospovidone type B  
Carmellose sodium  
Sodium carbonate, anhydrous  
Calcium stearate

#### *Tablet coating*

Poly(vinyl alcohol)  
Talc  
Titanium dioxide (E 171)  
Macrogol 3350  
Soya lecithin  
Iron oxide yellow (E 172)  
Sodium carbonate, anhydrous  
Methacrylic acid-ethyl acrylate copolymer (1:1)  
Sodium laurilsulfate  
Polysorbate 80  
Triethyl citrate

### 6.2 Incompatibilities

Not applicable.

### 6.3 Shelf life

For Alu-Alu blisters: 5 years

For HDPE bottles: 5 years

After first opening of the bottle use the medicinal product within three months.

#### **6.4 Special precautions for storage**

Do not store above 25°C.

#### **6.5 Nature and contents of container**

Alu/Alu blisters containing 7 or 14 gastro-resistant tablets or HDPE bottles with PP closure with a desiccant container containing 7 or 14 gastro-resistant tablets.

Not all pack sizes may be marketed.

#### **6.6 Special precautions for disposal**

No special requirements.

### **7 MARKETING AUTHORISATION HOLDER**

Clonmel Healthcare Ltd  
Clonmel  
Co. Tipperary  
Ireland

### **8 MARKETING AUTHORISATION NUMBER**

PA0126/220/001

### **9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of First Authorisation: 1st April 2011  
Date of Last Renewal: 17th November 2015.

### **10 DATE OF REVISION OF THE TEXT**

December 2019